Literature DB >> 3063912

A murine monoclonal antibody against Klebsiella capsular polysaccharide is opsonic in vitro and protects against experimental Klebsiella pneumoniae infection.

M Trautmann1, S J Cryz, J C Sadoff, A S Cross.   

Abstract

Murine monoclonal antibodies (mAb) of the immunoglobulin M class specific for the K2 capsular polysaccharide (CPS) of Klebsiella were isolated. One such mAb, termed III/5-1, was selected for further study. This mAb promoted the uptake and killing of Klebsiella pneumoniae K2 strains by human granulocytes and activated complement after contact with the bacteria. The efficiency of mAb-mediated phagocytosis and complement activation was inversely related to the amount of capsular material produced by the test strain. MAb III/5-1 was found to be effective at preventing fatal experimental K. pneumoniae K2 sepsis when administered prophylactically, the degree of protection being dependent upon the amount of CPS produced by the challenge strain.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3063912     DOI: 10.1016/0882-4010(88)90020-4

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  10 in total

1.  Salicylate-enhanced exposure of Klebsiella pneumoniae subcapsular components.

Authors:  R J Salo; P Domenico; J M Tomás; D C Straus; S Merino; V J Benedí; B A Cunha
Journal:  Infection       Date:  1995 Nov-Dec       Impact factor: 3.553

2.  Salicylate or bismuth salts enhance opsonophagocytosis of Klebsiella pneumoniae.

Authors:  P Domenico; R J Salo; D C Straus; J C Hutson; B A Cunha
Journal:  Infection       Date:  1992 Mar-Apr       Impact factor: 3.553

3.  Effects of MICs and sub-MICs of antibiotics on production of capsular polysaccharide of Klebsiella pneumoniae.

Authors:  T K Held; C Adamczik; M Trautmann; A S Cross
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

4.  Monoclonal antibody against Klebsiella capsular polysaccharide reduces severity and hematogenic spread of experimental Klebsiella pneumoniae pneumonia.

Authors:  T K Held; M Trautmann; M E Mielke; H Neudeck; S J Cryz; A S Cross
Journal:  Infect Immun       Date:  1992-05       Impact factor: 3.441

5.  Murine monoclonal antibodies to Klebsiella pneumoniae protect against lethal endotoxemia and experimental infection with capsulated K. pneumoniae.

Authors:  E Mandine; M F Salles; R Zalisz; M Guenounou; P Smets
Journal:  Infect Immun       Date:  1990-09       Impact factor: 3.441

6.  Protective effect of antilipopolysaccharide monoclonal antibody in experimental Klebsiella infection.

Authors:  T Rukavina; B Tícac; M Susa; N Jendrike; S Jonjíc; P Lucin; R Marre; M Doríc; M Trautmann
Journal:  Infect Immun       Date:  1997-05       Impact factor: 3.441

7.  Binding to and opsonophagocytic activity of O-antigen-specific monoclonal antibodies against encapsulated and nonencapsulated Klebsiella pneumoniae serotype O1 strains.

Authors:  T K Held; N R Jendrike; T Rukavina; R Podschun; M Trautmann
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

8.  A murine monoclonal antibody defines a unique epitope shared by Klebsiella lipopolysaccharides.

Authors:  M Trautmann; K Vogt; C Hammack; A S Cross
Journal:  Infect Immun       Date:  1994-04       Impact factor: 3.441

9.  Proinflammatory cytokines in antilipopolysaccharide immunity against Klebsiella infections.

Authors:  Tomislav Rukavina; Vanja Vasiljev; Brigita Ticac
Journal:  Mediators Inflamm       Date:  2005-06-09       Impact factor: 4.711

Review 10.  Klebsiella pneumoniae capsule polysaccharide as a target for therapeutics and vaccines.

Authors:  Clement Opoku-Temeng; Scott D Kobayashi; Frank R DeLeo
Journal:  Comput Struct Biotechnol J       Date:  2019-10-25       Impact factor: 7.271

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.